News Conference News ACC 2025 EARLY TAVR: Delaying Valve Replacement Increases Risk of Poor Outcomes L.A. McKeown April 07, 2025
News Conference News ACC 2025 More ALIGN-AR Data Bolster Potential for a Dedicated AR Device Yael L. Maxwell March 30, 2025
News Conference News ACC 2025 Dapagliflozin Works Well for High-Risk TAVI Patients With HF: DapaTAVI Caitlin E. Cox March 30, 2025
News Conference News ACC 2024 Another Win for TAVI in Patients at Low-to-Intermediate Risk: DEDICATE-DZHK6 Yael L. Maxwell April 08, 2024
News Conference News ACC 2023 Self-Expanding TAVI Holds Up to Surgery Out to 3 Years in Low-Risk Patients Todd Neale March 05, 2023
News Conference News ACC 2022 Self-Expanding TAVI Looks More Durable Than SAVR at 5 Years Michael O'Riordan April 04, 2022
News Conference News ACC 2021 Apixaban Curbs Subclinical Thrombosis After TAVI in Patients Without Prior OAC Michael O'Riordan May 17, 2021
News Conference News ACC 2021 ATLANTIS: Apixaban Has No Benefit Over Standard of Care Post-TAVI Yael L. Maxwell May 15, 2021
News Conference News ACC 2020 Edoxaban May Be Alternative to Warfarin After Surgical Valve Implantation or Repair L.A. McKeown April 07, 2020
News Conference News ACC 2020 PARTNER 3: TAVR Now Noninferior to Surgery at 2 Years in Low-Risk Patients Yael L. Maxwell March 29, 2020
News Conference News ACC 2020 A-fib Patients Undergoing TAVR Do Better With OAC Alone: POPular TAVI Todd Neale March 29, 2020
News Conference News ACC 2019 My Takeaways From ACC 2019: Breaking With Embargoes? Despite the Drama, Embargoes Set to Stay Shelley Wood April 05, 2019
News Conference News ACC 2019 Low-Risk Trials Cement a Role for TAVR Alongside—or in Place of—Surgery Michael O'Riordan March 17, 2019
News Conference News ACC 2018 Urgent/Emergent TAVR: Risky but Rewarding, TVT Registry Data Hint Caitlin E. Cox March 19, 2018
News Conference News ACC 2017 SURTAVI Lends More Support to Use of TAVR in Intermediate-Risk Patients Todd Neale March 17, 2017
News Conference News ACC 2016 TAVR With Sapien XT Noninferior to Surgery in Intermediate-Risk Patients, With a Win for Transfemoral Shelley Wood April 02, 2016
News Conference News ACC 2015 Thirty-day Outcomes with Sapien 3 Lowest Seen with Balloon-Expandable TAVR Yael L. Maxwell March 15, 2015
News Conference News ACC 2015 Follow-up TAVR Studies Reassure About Valve Durability, Outcomes Todd Neale March 15, 2015
News Conference News ACC 2014 TAVR With the CoreValve Device Superior to Surgery at 1 Year Yael L. Maxwell March 29, 2014